Viatris Inc
NASDAQ:VTRS
Viatris Inc
Cash Equivalents
Viatris Inc
Cash Equivalents Peer Comparison
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Viatris Inc
NASDAQ:VTRS
|
Cash Equivalents
$1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
35%
|
CAGR 10-Years
15%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Equivalents
$3.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-15%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Equivalents
$9.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
6%
|
|
Pfizer Inc
NYSE:PFE
|
Cash Equivalents
$719m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-13%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Equivalents
$5.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Equivalents
$2.5B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
See Also
What is Viatris Inc's Cash Equivalents?
Cash Equivalents
1B
USD
Based on the financial report for Mar 31, 2024, Viatris Inc's Cash Equivalents amounts to 1B USD.
What is Viatris Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
15%
Over the last year, the Cash Equivalents growth was 100%. The average annual Cash Equivalents growth rates for Viatris Inc have been 8% over the past three years , 35% over the past five years , and 15% over the past ten years .